Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has plunge by 0.37relation to previous closing price of 24.20. Nevertheless, the company has seen a 0.70% surge in its stock price over the last five trading sessions. zacks.com reported 2025-05-06 that The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
Additionally, the 36-month beta value for SMMT is -0.94. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SMMT is 111.14M and currently, short sellers hold a 22.58% ratio of that float. The average trading volume of SMMT on May 08, 2025 was 4.01M shares.
SMMT’s Market Performance
The stock of Summit Therapeutics Inc (SMMT) has seen a 0.70% increase in the past week, with a 40.24% rise in the past month, and a 16.89% gain in the past quarter. The volatility ratio for the week is 9.48%, and the volatility levels for the past 30 days are at 14.20% for SMMT. The simple moving average for the past 20 days is -4.17% for SMMT’s stock, with a 26.56% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Citigroup repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Citigroup is $35 based on the research report published on March 26, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to SMMT, setting the target price at $30 in the report published on March 12th of the current year.
SMMT Trading at 11.92% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.19% of loss for the given period.
Volatility was left at 14.20%, however, over the last 30 days, the volatility rate increased by 9.48%, as shares surge +45.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.12% upper at present.
During the last 5 trading sessions, SMMT rose by +0.70%, which changed the moving average for the period of 200-days by +176.49% in comparison to the 20-day moving average, which settled at $25.35. In addition, Summit Therapeutics Inc saw 36.12% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SMMT
The total capital return value is set at -0.48. Equity return is now at value -123.93, with -85.89 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -26.84. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -30.27.
Currently, EBITDA for the company is -212.85 million with net debt to EBITDA at 1.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.63.
Conclusion
In conclusion, Summit Therapeutics Inc (SMMT) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
